Monthly Archives: June 2013
Capecitabine Instead of Gemcitabine in Locally Advanced Pancreatic Cancer ?
Overshadowed perhaps by the positive results of Von Hoff and colleagues’ research on Abraxane plus gemcitabine for advanced pancreatic cancer (ductal adenocarcinoma of the pancreas), an interesting study on the treatment of LOCALLY ADVANCED pancreatic cancer was presented at the recent ASCO Gastrointestinal Cancers Symposium in San Francisco late January. In locally advanced cancer of […]
BRCA Gene Mutations and Risk of Pancreatic Cancer
BRCA1 and BRCA2 genes are important in the repair and upkeep of DNA. Mutations in these genes confer a strong tendency to not only more widely known breast cancer, but to other kinds of cancers as well – including contributing to some amount of pancreatic cancer (ductal adenocarcinoma of the pancreas). Now, researchers from the […]
Watchful Waiting for Small Nonfunctioning Pancreatic Neuroendocrine Tumors ?
Pancreatic neuroendocrine tumors can roughly be divided into functioning and non-functioning categories. The functioning tumors produce an abundance of a given hormone such that the clinical effects of this overabundance can be observed or felt by physicians and/or patients. Non-functioning pancreatic neuroendocrine tumors produce no hormone, or produce such hormones in sub-clinical quantity, or produce […]
Lack of Pancreatic Cancer Radiologic Improvement May NOT be an Accurate Measure of Neoadjuvant Success – an important and intriguing finding.
Researchers from the University of Texas / MD Anderson Cancer Center published an interesting recent study in the journal Cancer on the treatment and assessment of so-called neoadjuvant therapy in borderline resectable pancreatic cancer (ductal adenocarcinoma of the pancreas). “Neoadjuvant” is a word that denotes typically the medical and/or radiological treatment of pancreatic cancer BEFORE […]
DNA Marker Differences in Asians vs. Europeans with Pancreatic Cancer
Canzian and estimable European colleagues including Dr. John Neoptolemos of Liverpool University (and again our Professor Markus Buchler of the University of Heidelberg / Pancreatica Science Board) in a February 2013 article in the Cancer Epidemiology, Biomarkers, and Prevention – a publication of the American Association for Cancer Research through their newly formed collaborative called […]